西菲德羅考
參見

1 2 3  . European Medicines Agency (EMA). 2020-02-24  [2020-04-29]. （原始内容存档于2020-09-17）.   本文含有此來源中屬於公有领域的内容。
↑  . Union Register of medicinal products.   [2023-03-03]. （原始内容存档于2023-05-25）.
1 2 3 4 5  . DailyMed. 2019-11-19  [2020-04-29]. （原始内容存档于2021-02-01）.
↑  Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C. . Journal of Clinical Pharmacology. May 2017, 57 (5): 584–591. PMC 5412848 . PMID 27874971. doi:10.1002/jcph.841.
1 2 3 4 5 6 7 8 9 10 11 12  . U.S. Food and Drug Administration (FDA) (新闻稿). 2019-11-14  [2019-11-15]. （原始内容存档于2019-11-16）.   本文含有此來源中屬於公有领域的内容。
↑  Choi JJ, McCarthy MW. . Expert Opinion on Investigational Drugs. February 2018, 27 (2): 193–197. PMID 29318906. S2CID 205768562. doi:10.1080/13543784.2018.1426745.
↑  Aoki T, Yoshizawa H, Yamawaki K, Yokoo K, Sato J, Hisakawa S,  et al. . European Journal of Medicinal Chemistry. July 2018, 155: 847–868. PMID 29960205. S2CID 49682995. doi:10.1016/j.ejmech.2018.06.014.
↑  Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JC, Ariyasu M,  et al. . The Lancet. Infectious Diseases. December 2018, 18 (12): 1319–1328. PMID 30509675. S2CID 54552812. doi:10.1016/S1473-3099(18)30554-1.
1 2 3 4 5  . U.S. Food and Drug Administration (FDA). 2019-11-14  [2020-04-29]. （原始内容存档于2020-08-06）.   本文含有此來源中屬於公有领域的内容。
1 2  Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ,  et al. . Drugs. February 2019, 79 (3): 271–289. PMID 30712199. S2CID 59541210. doi:10.1007/s40265-019-1055-2.
1 2  . U.S. Food and Drug Administration (FDA). 2019-12-19  [29 April 2020-04-29]. （原始内容存档于2021-04-05）.  请检查|access-date=中的日期值 (帮助)
↑  . Drugs.com.   [2020-09-29]. （原始内容存档于2020-11-04） （英语）.
↑  World Health Organization. . Geneva: World Health Organization. 2021. hdl:10665/345533 . WHO/MHP/HPS/EML/2021.02.
↑  Matsunaga Y, Echols R, Katsube T, Yamano Y, Ariyasu M, Nagata TD. . American Journal of Respiratory and Critical Care Medicine (Abstract). May 2018  [20 September 2020]. doi:10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A3290 (不活跃 2024-01-31). （原始内容存档于2022-02-18）.  已忽略未知参数|article-number= (帮助) 含有連結內容需訂閱查看的頁面 (link)
↑  Choby JE, Ozturk T, Satola SW, et al. Widespread cefiderocol heteroresistance in carbapenem- resistant Gram-negative pathogens. Lancet Infect Dis 2021; 21: 597-598
↑   (PDF). Epidemiologisches Bulletin 36/2022. 2022-09-08  [2024-06-21]. （原始内容存档 (PDF)于2024-09-27）.
↑  Karakonstantis S, Rousaki M, Kritsotakis EI. . Antibiotics. May 2022, 11 (6): 723. PMC 9220290 . PMID 35740130. doi:10.3390/antibiotics11060723 .
↑  Sato T, Yamawaki K. . Clinical Infectious Diseases. November 2019, 69 (Suppl 7): S538–S543. PMC 6853759 . PMID 31724047. doi:10.1093/cid/ciz826.
↑  Matthews-King A. . The Independent. 2018-10-26  [2018-10-26]. （原始内容存档于2021-10-09）.
↑  Newey S. . The Telegraph. 2018-10-26  [2018-10-26]. ISSN 0307-1235. （原始内容存档于2019-04-12）.
↑  Simpson DH, Scott P. . Lo KK  (编). . Elsevier. 2017  [2024-06-21]. ISBN 978-0-12-803887-1. （原始内容存档于2021-02-25）.
↑  Saisho Y, Katsube T, White S, Fukase H, Shimada J. . Antimicrobial Agents and Chemotherapy. March 2018, 62 (3): 1–12. PMC 5826143 . PMID 29311072. doi:10.1128/AAC.02163-17.
↑  Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R,  et al. . Antimicrobial Agents and Chemotherapy. December 2016, 60 (12): 7396–7401. PMC 5119021 . PMID 27736756. doi:10.1128/AAC.01405-16.
↑  Principe L, Lupia T, Andriani L, Campanile F, Carcione D, Corcione S,  et al. . Pharmaceuticals. April 2022, 15 (4): 463. PMC 9028825 . PMID 35455461. doi:10.3390/ph15040463 .
↑  El-Lababidi RM, Rizk JG. . The Annals of Pharmacotherapy. December 2020, 54 (12): 1215–1231. PMID 32522005. S2CID 219586396. doi:10.1177/1060028020929988.